Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rheumatoid Arthritis
Biotech
Lilly changes lead psoriasis program from $2.4B Dice buyout
Lilly kicked DC-806 to the curb as part of a third-quarter cull that also affected the PD-1 autoimmune prospect peresolimab.
Nick Paul Taylor
Oct 30, 2024 10:00am
Fierce Biotech Bureau of Investigations seeks ACR poster burglar
Nov 16, 2023 12:59pm
Aclaris abandons one MK2 inhibitor over latest phase 2 fail
Nov 13, 2023 8:22am
J&J preps 'pipeline in a product' from Momenta for pivotal year
Feb 27, 2023 9:40am
Merck KGaA pays Aqilion €10M to tackle tough autoimmune target
Feb 16, 2023 6:00am
Pfizer punts pair of orphan drugs amid rare disease R&D rethink
Jan 31, 2023 9:15am
